High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study

Journal article

Peer reviewed

K.S. Tewari, M. Sill, D.H. Moore, H.J. Long, R.T. Penson, H. Huang, L.M. Landrum, A. Oaknin, H. Michael, B.J. Monk, …

Gynecologic oncology, Vol.133, pp.60-60

06/2014

Metrics

1 Record Views

Title: High-risk patients with recurrent/advanced cervical cancer may derive the most benefit from antiangiogenesis therapy: A Gynecologic Oncology Group (GOG) study
Creators: K.S. Tewari - University of California, Irvine
M. Sill - Gynecologic Oncology Group
D.H. Moore - Oncology Specialists
H.J. Long - Mayo Clinic in Arizona
R.T. Penson - Massachusetts General Hospital
H. Huang - Gynecologic Oncology Group
L.M. Landrum - Oklahoma City University
A. Oaknin - Spanish Ovarian Cancer Research Group
H. Michael - Indiana University
B.J. Monk - University of Arizona
L.M. Ramondetta - The University of Texas MD Anderson Cancer Center
T.J. Reid - University of Cincinnati
M.M. Leitao - Memorial Sloan Kettering Cancer Center
Publication Details: Gynecologic oncology, Vol.133, pp.60-60
Publisher: Elsevier Inc
Identifiers: 991005969145202656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article